HPTN 077

Principal Investigator(s):Raphael J. Landovitz
Objective:Evaluate the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.
Prevention Option(s):PrEP
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionOne GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744 at Weeks 5, 17, and 29.
Mode of DeliveryIntramuscular, Tablet
Official Code: NCT02178800
Trial Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Start Date
End Date
February 1, 2015
July 31, 2017
Age range: 18 Years ↔ 65 Years
Population:Cisgender Men, Cisgender Women